<code id='1BACB1397A'></code><style id='1BACB1397A'></style>
    • <acronym id='1BACB1397A'></acronym>
      <center id='1BACB1397A'><center id='1BACB1397A'><tfoot id='1BACB1397A'></tfoot></center><abbr id='1BACB1397A'><dir id='1BACB1397A'><tfoot id='1BACB1397A'></tfoot><noframes id='1BACB1397A'>

    • <optgroup id='1BACB1397A'><strike id='1BACB1397A'><sup id='1BACB1397A'></sup></strike><code id='1BACB1397A'></code></optgroup>
        1. <b id='1BACB1397A'><label id='1BACB1397A'><select id='1BACB1397A'><dt id='1BACB1397A'><span id='1BACB1397A'></span></dt></select></label></b><u id='1BACB1397A'></u>
          <i id='1BACB1397A'><strike id='1BACB1397A'><tt id='1BACB1397A'><pre id='1BACB1397A'></pre></tt></strike></i>

          Home / fashion / explore

          explore


          explore

          author:explore    Page View:5897
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In